Latest Breaking News On - Adverum biotechnologies - Page 9 : comparemela.com

Adverum Biotechnologies, Inc Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies, Inc. announced that Romuald Corbau, Ph.D., has joined Adverum as the company?s chief scientific officer. Dr. Corbau will serve as a member of Adverum?s executive committee..

United statesBaden wübergUnited kingdomRomuald corbauCentre for innovationTranslational departmentLille universityAdverum biotechnologies incAdverum biotechnologiesChief scientificVice presidentChief scientific officerTranslational leadSpark therapeuticsDrug discovery

DelveInsight Business Research, LLP: AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032)

DelveInsight Business Research, LLP: AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesOlenasufligene relduparvovecRoche pharmaGensight biologicsNeurotherapy bioMeira gtxShruti thakurAstellas pharmaScout bioUniqure biopharmaPrnewswire delveinsightChiesi farmaceuticiEli lillyCapsida biotherapeuticsSelecta biosciencesBridgebio pharma

AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032)

/PRNewswire/ DelveInsight s AAV Vectors in Gene Therapy Market Insights report includes a comprehensive understanding of current treatment practices,.

United statesUniqure biopharmaEli lillyRoche pharmaScout bioPrnewswire delveinsightNeurotherapy bioGensight biologicsOlenasufligene relduparvovecAstellas pharmaChiesi farmaceuticiCapsida biotherapeuticsSelecta biosciencesBridgebio pharmaShruti thakurMeira gtx

Marquette Asset Management LLC Has $90,000 Stock Holdings in Adverum Biotechnologies, Inc (NASDAQ:ADVM)

Marquette Asset Management LLC decreased its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) by 50.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 60,120 shares of the biotechnology company’s stock after selling 61,273 shares during the period. Marquette Asset Management LLC owned […]

Cantor fitzgeraldAdverum biotechnologies company profileVr adviserTopco ltdWorth venture partnersAdverum biotechnologies incMarquette asset managementAdverum biotechnologiesFree reportAsset managementVenture partnersGet free reportAdverum biotechnologies dailyNasdaq advmSec filingsHedge fund holdings

Comparing Adverum Biotechnologies (NASDAQ:ADVM) & bluebird bio (NASDAQ:BLUE)

Comparing Adverum Biotechnologies (NASDAQ:ADVM) & bluebird bio (NASDAQ:BLUE)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesRedwood cityGensight biologicsAdverum biotechnologies incAvalanche biotechnologies incGenetix pharmaceuticals incOrchard therapeuticsVirovek incUniversity of californiaAdverum biotechnologiesGet free reportLexeo therapeuticsAvalanche biotechnologiesGenetix pharmaceuticalsAdverum biotechnologies daily